72
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The FDA has sharply cut back on public advisory committee meetings, and this morning STAT’s Lizzy Lawrence explains what she’s hearing from industry leaders, patients, and academic experts on the issue.
Also, Xenon is posting impressive Phase 3 epilepsy results, and generic semaglutide could be produced for just a few dollars a month once patents expire, according to a new analysis.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
